Celldex Therapeutics Inc (CLDX)

Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Celldex Reports First Quarter Financial Results and Provides Corporate Update

Enrollment completed six months ahead of guidance in both barzolvolimab Phase 3 chronic spontaneous urticaria...

Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors

Form ARS - Annual Report to Security Holders

Form DEF 14A - Other definitive proxy statements

Celldex to Present at Upcoming Investor Conference

HAMPTON, N.J., April 13, 2026 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) announced today that management will...

Celldex Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares

HAMPTON, N.J., April 06, 2026 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (“Celldex” or the “Company”...

Form 424B5 - Prospectus [Rule 424(b)(5)]

Form 8-K - Current report

Celldex Announces Pricing of $300 Million Public Offering of Common Stock

HAMPTON, N.J., April 01, 2026 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (“Celldex” or the “Company”...

Form 424B5 - Prospectus [Rule 424(b)(5)]

Celldex Announces Proposed Public Offering of Common Stock

HAMPTON, N.J., April 01, 2026 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (“Celldex” or the “Company”...